alain h. litwin, m.d., m.p.h. irene j. soloway, r.p.a. albert einstein college of medicine...
TRANSCRIPT
![Page 1: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/1.jpg)
Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A.
Albert Einstein College of Medicine Montefiore Medical Center
November 2, 2012
Engaging Drug Users in Care andTreatment of Chronic Hepatitis C
![Page 2: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/2.jpg)
Outline
• Why do we need integrated models of HCV Care?• HCV Peer Program at Einstein• Models of HCV Care at Einstein
– Multidisciplinary on-site treatment– Directly Observed Treatment (DOT)– Concurrent Group Treatment
• Case Study• Next Steps
![Page 3: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/3.jpg)
Significance• IDUs are largest group of HCV-infected persons in
industrialized countries ~ 60% in U.S. (Shepard et al, 2005)– > 75% of new infections in IDUs– Up to 90% of IDUs in methadone clinics have HCV
• HCV prevalence in non-injecting DUs 2.3-17% (Sheinmann et al, 2007)
• Approximately 1200 opiate treatment programs (OTPs) and 265,000 patients in the United States.
• Over 1,000,000 patients have been prescribed buprenorphine in the United States.
![Page 4: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/4.jpg)
Low Treatment Uptake among IDUs
• Before 2001, guidelines discouraged treatment of IDUs• Since 2002, revised guidelines advocate treating IDUs on a
case by case basis• However, HCV treatment rates among IDUs remain low:
overall rates of treatment uptake among IDUs: 1%- 6%– Baltimore cohort of 597 HCV-infected IDUs (Mehta et al, 2007)
• 70% aware of HCV treatment• 14% evaluated for treatment• 6% initiated treatment
– Vancouver community-based cohort of 2118 persons, mainly illicit drug users (Grebely et al, 2009)
• 64% HCV Ab+• 1.1% initiated treatment
![Page 5: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/5.jpg)
Hepatitis C Treatment for IDUs: A Review of the Available Evidence (Hellard et al, 2009)
– Systematic review of 22 studies of pegylated interferon plus ribavirin in HCV-infected IDUs
• Median SVR rate among IDUs receiving PEG IFN + RBV: 54% • Similar SVR rates between IDUs and non-IDUs • In 3 large trials of treatment with PEG IFN + RBV (excluded
drug users): 54% - 63% SVR– 13 studies included IDUs in drug treatment programs
• Median SVR rate 48% • In 8 studies HCV treatment administered in multidisciplinary
programs providing care for HCV, addiction, and mental health
– Median SVR rate 49% (range 26%–94%)
![Page 6: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/6.jpg)
Why do we need integrated models of hepatitis C care?
• 228 drug users (former and current) with chronic hepatitis C referred to liver clinic (Fishbein et al, 2004)– 127 (56%) accepted referral– 54 (24%) arrived for evaluation– 4 (2%) initiated treatment (no SVRs noted)
• 11% of patients with chronic hepatitis C who were evaluated at the liver clinic initiated antiviral treatment. (Feuerstadt et al, 2010)
• 76% of patients from opiate dependence treatment program interested in HCV treatment after hearing the risks and benefits. (Walley et al, 2005)
![Page 7: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/7.jpg)
Why do we need on-site treatment?(Feuerstadt et al, 2010)
Genotype 1 - Group
SVR Unable to tolerate
Hispanic (n=92) 10.9% 31.5%
African-American (n=51)
13.7% 7.8%
Caucasian (n=16)
25.0% 31.2%
![Page 8: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/8.jpg)
Annual age-adjusted mortality rates from hepatitis B and hepatitis C virus and HIV infections listed as causes of death in the United States between 1999 and 2007.
Ly K N et al. Ann Intern Med 2012;156:271-278
©2012 by American College of Physicians
![Page 9: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/9.jpg)
SVR is Associated with Reduced Risk All-Cause Mortality (Backus et al; 2011)
![Page 10: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/10.jpg)
Effectiveness vs Efficacy(El-Serag et al, 2010)
![Page 12: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/12.jpg)
Integrating HCV care with opiate agonist treatment at Albert Einstein
• Network of community-sited opiate agonist treatment programs in the Bronx, NY
• Comprehensive on-site primary care
• 3400 patients– 59% Latino/a, 23% African American, 18%
Caucasian– 65% HCV Antibody positive– 50% chronic HCV infection
![Page 13: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/13.jpg)
Integrating HCV Care with Opioid Agonist
Therapy at Einstein
Opiate Agonist Treatment
Site: Article 28 facility
Staff: Internist or family practice + PAPart-time psychiatristSubstance abuse counselors, HCV Coordinator and Educator, Social Worker and Nursing.
Services:Opioid agonist therapyComprehensive on-site 1º care General, HCV, HIV, GynPsych evaluation and treatmentSupport groups and peer educatorsLaboratory testing and EKGUrine toxicology testing
HospitalInterventional radiologistHepatologistTransplant centerPathologistEST, optho, derm, etc.Lab
![Page 14: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/14.jpg)
Hepatitis C Evaluation and Treatment Protocol
• Universal testing - HCV antibody on all patients• HAV and HBV vaccines offered • Alcohol screening and counseling • HCV+ patients offered on-site evaluation and possible
treatment– protocol and AASLD guidelines
• Multidisciplinary team: medical providers (MD and PA), nurses, substance abuse counselors, and HCV staff (Program Coordinator and HCV Educator)
![Page 15: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/15.jpg)
Roots“We represent a coalition of patients, providers, family members and friends: all affected by the hepatitis C epidemic in our South Bronx Community.
People in methadone maintenance must have access to hepatitis C resources. We work to ensure that current and former drug users have access to treatment for both substance abuse and
hepatitis C.”
![Page 16: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/16.jpg)
Peer Program Evolution
![Page 17: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/17.jpg)
HCV Peer Program
• Co-facilitation of groups (pre-treatment and group treatment)
• Escorts to liver biopsy and other off-site appointments (initiated by peer)
• Clinic events (e.g. recovery day)• Outreach within the clinic• Outreach within the community (health fairs, harm reduction programs, and primary care)
• Participation with advocacy activities (e.g. task force)
![Page 18: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/18.jpg)
![Page 19: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/19.jpg)
Liver Biopsy Program Results
• 100 patients scheduled (2005 – 2008)– Counseling and scheduling by Hepatitis Educator– 68% Male– 61% Latino; 32% African American; 7% Caucasian– 42% HIV/HCV coinfected
• 80 patients (80%) showed up to liver biopsy – some patients required multiple appointments (up to 3 referrals)
• 41 patients (41%) used escorts– Peers showed up 100% of the time
![Page 20: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/20.jpg)
![Page 21: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/21.jpg)
Methadone and Interferon(Berk et al, 2007)
![Page 22: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/22.jpg)
Methadone and Telaprevir(van Heeswijk et al, EASL 2011)
![Page 23: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/23.jpg)
Buprenorphine and Telaprevir(Luo et al, HEP DART 2011)
![Page 24: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/24.jpg)
Integrated On-Site Treatment (n=73)
Retrospective, observational chart review of on-site HCVtreatment (pegylated interferon and ribavirin) provided to 73drug users between January, 2003 and December, 2005:
– 90% IDU– 49% recently used illicit drugs– 67% Latino, 21% Caucasian, and 12% African American– 32% HIV-infected– 67% current psychiatric illness– 40% advanced fibrosis on liver biopsy – 68% genotype 1– 38% attended HCV support groups
Litwin et al, 2005 and Litwin et al, 2009
![Page 25: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/25.jpg)
HCV Treatment Outcomes
– 86% completed ≥12 weeks of treatment– 45% SVR
• Genotype 1 - 40% SVR– HIV/HCV coinfected equivalent SVR (43%) as
HCV-monoinfected patients (46%) – No association between illicit drug use during
HCV treatment and virological outcomes• active illicit drug use during treatment (37%)
![Page 26: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/26.jpg)
How many patients can be evaluated and treated with an integrated model of care?
159 HCV + eligible for on-site services in one clinic, and 125(78%) chose on-site HCV care
• 83 with chronic hepatitis C (VL +)– 25 biopsies performed (7 required no
treatment due to low stage disease)– 21 initiated treatment, 8 (38%) achieved SVR– 17 with contraindications to HCV treatment– 45 (54%) reached primary goal of completion
of evaluation or treatment initiation
Harris et al, 2010
![Page 27: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/27.jpg)
HCV DOT Study (Litwin et al, 2011)
![Page 28: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/28.jpg)
Methods• Randomized, controlled trial• Subjects in both study arms receive once-weekly directly-
administered pegylated interferon injections• Subjects randomized to either ribavirin by directly observed
therapy (DOT) or treatment as usual (TAU)• Subjects in DOT arm receive between 3 and 6 directly
observed ribavirin doses weekly administered by nursing staff at same time and on the same schedule as subjects receive methadone. – Evening, non-clinic and weekend ribavirin doses individually packaged as take-
home doses.• Subjects in TAU arm self-administer twice-daily ribavirin at
home
![Page 29: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/29.jpg)
![Page 30: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/30.jpg)
Results (n=40)
![Page 31: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/31.jpg)
Results (n=40)
![Page 32: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/32.jpg)
Ribavirin adherence (n=40)Pill Count Adherence Rate
0.50
0.60
0.70
0.80
0.90
1.00
4 8 12 16 20 24
Week
DOT
TAU
Week DOT adherence (%) TAU adherence (%)
Week 4 90 78
Week 8 89 81
Week 12 88 80
Week 24 87 79
![Page 33: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/33.jpg)
Ribavirin adherence (n=40)
• Mixed effects linear model– Study arm, time, and interaction
of study arm and time
• Over 24 weeks, pill count adherence higher for DOT than TAU subjects
• 88% DOT vs. 77% TAU (p =0.02)
![Page 34: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/34.jpg)
Pegylated interferon adherence (n=40)
• Subjects in both arms received weekly directly administered pegylated interferon
• 96% DOT vs. 94% TAU(p=NS)
![Page 35: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/35.jpg)
Treatment Outcomes
![Page 36: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/36.jpg)
Treatment Outcomes
• SVR predicted based on following factors (data from large HCV trials)– Genotype (1/4 vs. 2/3)– HIV+ vs HIV-– Race/ethnicity (White, Black, Latino)– Treatment-naive vs treatment-experienced
• Predicted SVR = 37% (32% , 42%)• Actual SVR = 42% (34% , 50%)
![Page 37: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/37.jpg)
DOT studies in United States -Opiate Agonist Treatment Programs
• Three U.S. DOT studies (Peg + RBV) demonstrate potential of DOT to increase rates of treatment initiation and SVR.
• Co-located model (Bruce et al, 2012): RCT of on-site DOT (Peg + RBV) (n=12) vs. off-site (n=9) – 12 of 12 in on-site DOT arm started treatment vs. 4 of 9 in off-site arm– 6 of 8 on-site DOT arm with SVR vs. 1 of 4 in off-site arm
• Off-site model (Bonkovsky et al, 2008): RCT of DOT (Peg only) (n=24) vs. self-administration (n=24). – Stepwise logistic regression analysis for SVR: (DOT vs. SA; OR 3.27,
95% CI 0.90–11.91, P = 0.073)• Off-site model (Taylor et al, 2012): Prospective trial of DOT (Peg +/- RBV)
Genotype 1 HIV/HCV coinfected patients (n=11)– 2 of 11 had SVR (18%)– 5 of 11 did not complete 12 weeks (45%)
![Page 38: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/38.jpg)
Once Daily DOT with PEG/RBV in Drug Users (Waizmann, 2010)
• German retrospective study of 49 HCV mono-infected IDUs enrolled in an opiate agonist treatment program with integrated model (methadone or buprenorphine)– No recent illicit drug use– 57% genotypes 2 / 3; 43% genotypes 1 / 4– Median age 30.1 years; median duration of infection 3.4 years– median BMI 23.7– median HCV viral load = 121,775 IU/ml– no HIV
• Patients seen once daily and received DOT with PEG-IFN alfa-2a once weekly and daily fixed dose of ribavirin 800 mg – 1200 mg.
• All received citalopram (2 weeks prior to HCV treatment)• 98% achieved SVR (48 out of 49)• Safety profile of ribavirin once daily not different than twice daily dosing in
this population
![Page 39: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/39.jpg)
HIV DOT Decreases Viral Load (Berg et al, 2011)
![Page 40: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/40.jpg)
HCV Concurrent Group Treatment at Einstein 2009 - present
![Page 41: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/41.jpg)
HCV Group Treatment at Einstein2009 - present
•Group orientations and individual HCV workup•Trial with placebo pillbox•4 - 12 patients form cohort and initiate treatment •Multiple cycles each year at two sites•Third site starting 2013•Flexible model: concurrent and rolling initiation•Both peg/ribavirin and triple therapy with DAAs•DOT with prepared pillboxes 60 patients as of October 2012
![Page 42: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/42.jpg)
HCV Group Treatment Model
Peer / Health Educator
• Sets up room: coffee, snacks
• Side effect surveys done• Weights and vitals taken• Group discussion co-
facilitated by Peer Educator and Health Educator
Provider
• Conducts semi -private individual visits
• Vitals and focused physical• Addresses adverse effects and
adherence• Administers peg interferon
injections and growth factors as needed
Conclude with patient milestones, updates and peer led meditation
![Page 43: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/43.jpg)
Incentives and Enhancements• Metrocards for initial 12 weeks• Coffee and snacks• Certificates and celebrations as patients complete
treatment milestones• Education/stories/games• Family friendly• Invited guests: physicians, students/residents,
organizations etc
![Page 44: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/44.jpg)
HCV Group Treatment Tools
![Page 45: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/45.jpg)
Group Treatment in Action
![Page 46: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/46.jpg)
HCV Group Treatment with peg/ribavirin (n =27)
• First 27 patients treated with peg/ribavirin• 70% Latino• 66% Genotype 1• 30% HIV co-infected• 59% pre-existing psychiatric illness• >58% recently used illicit drugs
• High rates of group attendance / retention• 89% of those initiated completed all group sessions• 4 of 27 patients discontinued for adverse events
• Virologic results• 44% genotype 1 achieved SVR
• Includes co-infected, cirrhotic, co-morbid disease
![Page 47: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/47.jpg)
Group Treatment Triple Therapy with Directly Acting Antivirals
• Telaprevir (Incivik) Boceprevir (Victrelis)
Q 7-9 hour dosing with 20 gram fat meal :4 hour window
Q 7-9 hour dosing with carb snack: 2 hour window
![Page 48: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/48.jpg)
Group Treatment Results with Direct Acting Antivirals (n=28)
Retrospective, observational chart review of HCVtreatment (pegylated interferon, ribavirin, and DAAs)provided to first 28 drug users between 8/ 2011 and 9/2012
• 93 % IDU• 57% recent positive urine tox (within 6 months)• 75% Latino, 21% African American, 4% Caucasian• 89% current psychiatric illness• 100% genotype-1• 11% discontinued treatment early• 86% <43 IU/ml or undetectable viral load at 4 weeks• 89% undetectable viral load at 24 weeks (n=19)• 81% end of treatment response (n=16)
![Page 49: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/49.jpg)
Group Treatment Benefits
For Patients
• Social support is built-in to
treatment
• Misconceptions addressed in
group discussions
• Reassurance by concurrent
participation of peers
• Fear of negative side effects
mitigated
• Side effects normalized
For Providers
• Frequent contact and close observation by providers and peers
• Co management of cohort enhances expertise and confidence
• Natural mentoring opportunity
• Break from “the usual”
![Page 50: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/50.jpg)
HCV Group Treatment Model Benefits: Peer Education
• Patients acquire information before, during, and after treatment
• Patients learn to communicate their knowledge and experience to others
• Patients who complete treatment come back to support others and reinforce core messages
• Natural segue to more formal peer educator role
![Page 51: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/51.jpg)
HCV Group Treatment: Challenges• Assembling cohort• Staff (Health Educator)• Protected time for Healthcare Provider • Funding (for metrocards)• Needs to be studied further
![Page 52: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/52.jpg)
Case Study E.O.• 32 year old Latino male with history of PTSD and
substance abuse• First heroin use age 17 , first IDU age 19 • Therapeutic Community (T.C.)
→relapse →detox →bupe/recovery groups• Aware of HCV+ status from T.C.• “Interested in HCV treatment” →pre-treatment
workup• Genotype and viral load done, patient offered
treatment
![Page 53: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/53.jpg)
Case Study E.O.
• Psychiatric assessment: “may need more time in recovery but no contraindications”
• Re-started on sertraline and quetiapine• Attended two HCV group treatment
orientations co-facilitated by peer educators
![Page 54: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/54.jpg)
E.O: Treatment Course• Starts Group Treatment on triple therapy with telaprevir• Week 4: ↓5 grams hgb ↓10% weight loss, increased depression, rash• Initiated growth factors, marinol, topical
steroids, psychiatric medication adjustments• Patient arrested week 8: central booking: “I
need my 20 grams fat”
![Page 55: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/55.jpg)
E.O. continued
• Patient gets married (wife also HCV+): brings wife to group on wedding day
• Graduates from outpatient drug treatment program
• Starts vocational training for electrical trade• Wife now seeking treatment for HCV
![Page 56: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/56.jpg)
Benefits of ModelPatient drivenEducation by peers and providersMultidisciplinaryDOTPsycho-social supportSupport for recoveryRole modeling by peers“Upward spiral”
![Page 57: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/57.jpg)
Einstein Model: Conclusions
• Drug users are interested in treatment, accept treatment recommendations, and are effectively treated.
• Integrated models of care involving peers, groups, and directly observed therapy (DOT) may be effective strategies to:– increase access to care – promote adherence , completion, and cure
• Adherence is more complex with triple therapy
![Page 58: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/58.jpg)
Future Studies: Intensive Models of HCV Care for Injection Drug Users
• Randomize 150 treatment-naive (HIV/HCV coinfected and HCV monoinfected) genotype-1 patients to three models of on-site care– Standard on-site care– DOT – Concurrent Group Treatment
• Outcomes: Adherence, completion, cure, and resistance
• What levels of adherence prevent resistance?• Cost and cost-effectiveness of each model
![Page 59: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/59.jpg)
![Page 60: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/60.jpg)
![Page 61: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/61.jpg)
![Page 62: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/62.jpg)
![Page 63: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/63.jpg)
![Page 64: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/64.jpg)
IFN-Free Regimens for Treatment-naive
• 94% SVR12 with 12 weeks of IFN-free triple therapy for G1 treatment-naive patients-ABT450/r once daily (ritonavir-boosted NS3 protease
inhibitor) + ABT333 twice daily (non-nucleoside NS5B inhibitor) + RBV
• 100% SVR4 with 24 weeks of IFN-free double therapy regimen for G1 treatment-naive patients-Daclatasvir once daily (NS5A inhibitor) + GS7977 once daily
(nucleotide NS5B inhibitor)
![Page 65: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/65.jpg)
Drug Interaction Chart
![Page 66: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/66.jpg)
Gloria Searson, MSW: Founding Director , Coalition for Positive Empowerment (COPE)
“With all of this exciting information, there is nothing
exciting for them.”
![Page 67: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/67.jpg)
Theory of Fundamental CauseDisparities in Care (Link and Phelan)
• SES is a “fundamental cause” of health and mortality disparities– money, knowledge, prestige, power, social connections
• SES disparities endure despite availability of more effective treatment
• When treatments more efficacious, disparities increase• In U.S., health care fragmented for all people, but people with
high SES mobilize necessary resources• Intensive models of HCV care which mobilize resources may
decrease associations between SES and HCV-related morbidity and mortality
![Page 68: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/68.jpg)
2009 AASLD Guidelines: Drug Users
“Treatment of HCV infection can be considered for persons even if they currently use illicit drugs or who are on a methadone maintenance program, provided they wish to take HCV treatment and are able and willing to maintain close monitoring…Persons who use illicit drugs should receive continued support from drug abuse and psychiatric counseling services as an important adjunct to treatment of HCV infection”
![Page 69: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/69.jpg)
Addiction treatment physicians and HCV treatment eligibility
![Page 70: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/70.jpg)
Integrated Models with Multidisciplinary Care and Peer Support (Grebely et al, 2010)
• 204 HCV Antibody+ illicit drug users within a clinic in Vancouver, Canada who accepted referral to a weekly HCV peer-support group– 53% of patients received HCV evaluation– 28% (n=50) received HCV treatment – 63% (n=19) SVR among those completing treatment
despite illicit drug use in 53%– First 4 weeks of support group attendance (2-4 groups
versus 1 group) predicted successful HCV assessment (OR: 6.0; 95% CI 3.3-11.1)
![Page 71: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/71.jpg)
2009 AASLD Guidelines: Alcohol
“Treatment should be individualized for people who currently use alcohol and who are willing to participate in a substance abuse or alcohol treatment program.”
![Page 72: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/72.jpg)
Integrated Care Model – Alcohol Dependence
(Le Lan et al, 2012) • Prospective, observational, case-controlled study of patients (n=73) of
HCV patients with alcohol dependence (ongoing consumption or < 6 months of abstinence)– 62% drinking at time of treatment– 34% abstinent < 3 months
• SVR 48% in patients with alcohol dependence vs 49% of controls
• Length of abstinence PRIOR to treatment did not predict SVR
• During HCV treatment, length of abstinence associated with SVR– abstinent (30%) – 65% SVR, – Low-risk consumption (34%) – 52% SVR– excessive consumption (36%) – 33% SVR
![Page 73: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/73.jpg)
Scaling Up in the United States• 1200 opiate treatment programs (OTPs) - 265,000 patients• Over one million patients prescribed buprenorphine • Majority of programs don’t offer HCV testing or treatment
either on-site or by contractual agreement (Bini et al, 2012)• Only 7.1% of patients receiving long-term treatment at OTPs
had regular contact with primary care provider.• National survey of addiction treatment physicians (Litwin et
al, 2007)– 9% providing on-site HCV treatment without referral– additional 31% willing if given appropriate training and resources
![Page 74: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/74.jpg)
Integrated Models of Care – Centralized Models
• Models of care take advantage of existing resources and access to patients with chronic hepatitis C– VA is a model program– Primary care centers such as FQHCs – Substance abuse treatment clinics– HIV clinics– Corrections– Other: mental health centers, mobile vans, shelters
![Page 75: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/75.jpg)
Integrated Models of Care -Decentralized Models
• Intensive Case Managers and Patient Navigators (Edlin and Carden; Check HepC Program in New York City)
• Peer escorts (Litwin et al, 2005)• Telemedicine (Arora et al, 2011)• Contingency Management
– Modest compensation (e.g. $20) for attending appointments combined with other strategies
• TB Clinic Infrastructure
![Page 76: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/76.jpg)
Future Directions (Gravitz, 2011)
![Page 77: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/77.jpg)
Future Directions (Edlin, 2011)
![Page 78: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/78.jpg)
![Page 79: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/79.jpg)
Effectiveness vs Efficacy(El-Serag et al, 2010)
![Page 80: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/80.jpg)
AcknowledgementsDoSA HCV Program Staff DoSA HCV Treatment TeamLauren Cockerham-Colas Medical AssistantsSheila Reynoso NursesRobert Roose PhysiciansMelissa Stein Physicians AssistantsPeer Leaders and Advisors Substance Abuse Counselors
HCV DOT Study DoSA Executive StaffJulia Arnsten Valerie BartlettAbigail Batchelder Sarah ChurchMichael Ciofoletti Ira MarionJoe HechtJennifer HidalgoMoonseong HeoXuan Li
![Page 81: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/81.jpg)
Acknowledgements
• National Institute of Drug Abuse• Robert Wood Johnson Foundation• New York State Department of Health• New York City Department of Health• Centers for Disease Control and Prevention
![Page 82: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/82.jpg)
Reasons patients not offered HCV treatment
71 (49%) patients not offered treatment
– mild liver fibrosis on biopsy (14)– AIDS - low CD4 count (14)– unstable chronic illnesses (14): cardiac disease (4); pulmonary disease (4); seizure
disorder (2); renal insufficiency (2); diabetes (1); hypertension (1)– decompensated cirrhosis (4)– malignancies (4): hepatocellular carcinoma (1); gastric carcinoma (1) ; multiple
myeloma (1); metastatic cervical carcinoma (1)– cytopenias (4): anemia (2); thrombocytopenia (2)– Insurance not accepted (4)– unstable drug use (3)– severe alcohol dependence (3)– unstable psychiatric illness (2)– autoimmune conditions (2): CREST syndrome(1); rheumatoid arthritis (1)– other illnesses (2): pancreatic fistula (1); abscess after hip replacement (1)– lost to follow-up (1)
![Page 83: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/83.jpg)
Drug Use Prior to Treatment and Adherence (Sylvestre et al, 2007)
![Page 84: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/84.jpg)
Drug Use During HCV Treatment and Adherence(Sylvestre et al, 2007)
![Page 85: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/85.jpg)
HIV DOT: Association between frequent drug use, treatment arm, and adherence (Nahvi et al, 2011)
![Page 86: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/86.jpg)
HCV Group Treatment Model Benefits: Peer Education
•Patients acquire information before, during, and after treatment
•Patients learn to communicate their knowledge and experience to others
•Patients who complete treatment come back to support others and reinforce core messages
•Natural segue to more formal peer educator role
![Page 87: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/87.jpg)
Daclatasvir (BMS-790052) QD (NS5A inhibitor) + asunaprevir (BMS-650032) BID (NS3 protease inhibitor) ± pegIFN/RBV for 24 wks
Combination Therapy for Null Responders
1. Lok A, et al. EASL 2011. Abstract 1356.2. Chayama K, et al. AASLD 2011. Abstract LB-4.
100
80
60
40
20
0
36
Daclatasvir + Asunaprevir
Daclatasvir + Asunaprevir + PR
SV
R24
(%
)
90 90*
N/A
US Study[1] Japan Study[2]
*all genotype 1b patients.
![Page 88: Alain H. Litwin, M.D., M.P.H. Irene J. Soloway, R.P.A. Albert Einstein College of Medicine Montefiore Medical Center November 2, 2012 Engaging Drug Users](https://reader036.vdocument.in/reader036/viewer/2022062516/56649e055503460f94af1040/html5/thumbnails/88.jpg)
Determinants of Successful Treatment with DAAs
• Treatment-naive vs. treatment-experienced• HCV subtype 1b vs. 1a• IL28B genotype CC vs. CT or TT genotypes• Drug potency and resistance barrier• Drug concentration (DDIs)• Liver histology: no cirrhosis vs. cirrhosis• Baseline resistance• Adherence to treatment• Aggressive side effect management• Drug safety and tolerability